From: Tumor infiltrating B-cells are increased in prostate cancer tissue
 | ALL (n = 53) |
---|---|
Mean age ± SD, years | 62 ± 6.8 |
 Race |  |
 Caucasian | 45 (84.9%) |
Other | 8 (15.1%) |
Mean BMI ± SD, Kg/m2 | 27.7 ± 3.6 |
Hypertension | 13 (24.5%) |
Hypercholesterolemia | 15 (28.3%) |
Diabetes | 5 (9.4%) |
Coronary artery disease | 4 (7.5%) |
5 Alpha-Reductase (Proscar/Avodart) | 8 (15.1%) |
Primary relative with prostate Ca | 17 (32.1%) |
Median PSA (IQR), ng/mL | 6.2 (4.2–9.8) |
Clinical T stage | Â |
 T1a-c | 24 (45.3%) |
 T2a-c | 25 (47.2%) |
 T3a-b | 4 (7.5%) |
Biopsy Gleason score | Â |
 ≤ 6 | 20 (37.7%) |
 7 | 17 (32.1%) |
 ≥ 8 | 16 (30.2%) |
D'Amico risk group | Â |
 Low risk | 10 (16.7%) |
 Intermediate risk | 9 (15.0%) |
 High risk | 15 (25%) |
 Recurrence | 26 (43.3%) |